在寻找有效的抗阿尔茨海默氏症药物方面的最新进展
Martyna Ogos1, Dorota Stary1, Marek Bajda1
1Department of Physicochemical Drug Analysis, Jagiellonian University Medical College, Medyczna Str. 9, 30-688 Kraków, Poland.
International journal of molecular sciences
|January 11, 2025
概括
多目标导向带 (MTDLs) 通过同时解决多种病理途径,为抗击阿尔茨海默病提供了一种有前途的方法. 本综述分析了从2020-2024年开发的MTDL,重点关注其活动和机制.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其特征是粉样质斑块和神经纤维状结.
- 目前的AD治疗提供了症状缓解,但不能阻止疾病的进展,通常只针对单一的病理机制.
- 阿尔茨海默病的多因素性质需要创新的治疗策略,以解决多种导致因素.
研究的目的:
- 审查和分析2020年至2024年期间针对阿尔茨海默病的多目标导向联结体 (MTDLs) 的发展.
- 研究新型抗阿尔茨海默氏症MTDLs的活性,作用机制和结合性.
- 突出MTDLs在克服AD单个向治疗的局限性的潜力.
主要方法:
- 对2020-2024年为阿尔茨海默病开发的MTDL进行了全面的文献搜索.
- 报告的体外和体内研究评估MTDL疗效的分析.
- 检查已识别的MTDLs的结构-活动关系和绑定配置文件.
主要成果:
- 几种新的MTDL在临床前研究中表现出显著的潜力,准了关键的AD病理,如粉样β,和神经炎症.
- MTDLs表现出多种作用机制,包括酶抑制,受体调节和抗氧化特性.
- 分析显示,对某些MTDLs有前途的结合亲和性和改善的药物动力学特征.
结论:
- 多目标导向带代表了阿尔茨海默病的有前途的治疗范式,提供了比传统单目标药物更全面的方法.
- 对MTDL的持续研究和开发对于推进阿尔茨海默氏症治疗策略至关重要.
- 审查的MTDL为设计下一代治疗药物来对抗阿尔茨海默病提供了基础.
相关概念视频
Alzheimer's Disease: Treatment
161
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
161
Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95
Dementia
94
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
94
Drug Therapy
37
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
37
Parkinson's Disease: Treatment
215
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
215


